<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: We report the first case of immunophenotypically confirmed primary hepatic Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> presenting with <z:hpo ids='HP_0006554'>acute liver failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The patient survived following an aggressive diagnostic approach followed by emergent chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>DISCUSSION: Data from the primary hepatic non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> literature show a survival rate of 87% at 5 years with combination regimens of chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>However, mortality rate in this population is 85% in patients with <z:hpo ids='HP_0006554'>acute liver failure</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: Primary hepatic Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> may respond well to emergent chemotherapy even in the setting of <z:hpo ids='HP_0006554'>acute liver failure</z:hpo> </plain></SENT>
</text></document>